· Published by Health Canada · Official notice
| Lot | Product Name | Market Authorization | Brand Product Name | Dosage Form | Strength |
|---|---|---|---|---|---|
| All | Taisho Pharmaceutical Pabron Gold A | No market authorization | Taisho Pharmaceutical Pabron Gold A | Granules | Guaifenesin 60 mg, Dihydrocodeine phosophate 8 mg, dl-Methylephedrine Hydrochloride 20 mg, Acetaminophen 300 mg, Chlorpheniramine Maleate 2.5 mg, Anhydrous Caffeine 25 mg, Riboflavin 4 mg |
Product sold without market authorization (DIN) in Canada. Product is labelled to contain dihydrocodeine phosphate that is listed on Schedule I of the Controlled Drugs and Substances Act. Product is labelled to contain guaifenesin, dl-methylephedrine hydrochloride, acetaminophen, chlorpheniramine maleate and caffeine that may pose a risk to health.